We hope to see you again soon!

You are now leaving Lundbeck UK's website (www.lundbeck.com/uk) for an external website. External links are provided as a resource to the viewer. Lundbeck UK are not responsible for the external website and its content.

UK-NOTPR-1010 | April 2022

Continue

Cancel

Business Development

Creating Value Together

We are tirelessly dedicated to restoring brain health for people living with psychiatric and neurological diseases. From early-stage science to commercialisation, partnerships are a key pillar in our strategy and in our ambition to become leaders within brain health.

Who we Are

Lundbeck is globally recognised as one of the leading companies within neurological and psychiatric disorders. 

 

Partnering with external specialists in their respective fields of brain disease is a cornerstone of our strategy, and we always strive to be the partner of choice. Lundbeck holds the knowledge, capabilities and financial stability to spur innovation, both through our internal laboratories and external partners.

 

We enter into partnerships recognising that your business strengths are different and complementary to our own. This is why we customise each partnership to ensure value creation and to translate today’s know-how into tomorrow’s advancements in life-changing therapies.

Our Partnering Process

We have a rigorous process to screen, assess, and execute on external opportunities ranging from technologies, pipeline assets, and company acquisitions. We use a tried-and-tested cross-functional approach to conduct an effective in-depth evaluation of every business development opportunity.

Our business development team works closely with internal stakeholders and subject matter experts to ensure an agile exchange, knowledge sharing and fast decision making. In this way, we aim to create the strongest possible foundation for a mutual understanding of how to shape the market for tomorrow.

 

Opportunities include commercial partnerships and acquisitions, strategic research and development (R&D) collaborations, access to assets, and supportive technologies.

Stage 1 – Initial evaluation

  • Initial scientific evaluation 
  • Identifying each candidate as a potential partnering opportunity
  • Evaluation of business hypothesis
  • Entry into a CDA (confidential disclosure agreement)

 

Stage 2 – Full evaluation

  • In-depth internal evaluation of confidential material to confirm scientific rationale
  • In-depth internal commercial assessment of business rationale
  • Initial business case development
  • Development of non-binding terms

 

Stage 3 - Due diligence and confirmation of business rationale

  • Completion of due diligence
  • External validation of business rationale, including market research, and exclusivity assessment
  • Confirmation of business case

 

Stage 4 - Negotiation and contracting

  • Negotiating deal terms and conditions
  • Finalising deal terms and conditions
  • Finalising contract

Areas of Interest

Our primary ambition is to find innovative projects and products that will advance neuroscience and develop novel and innovative treatments for patients. By combining our internal R&D capabilities with external alliances, we significantly broaden the opportunities to achieve our end goal. These include:

 

  • Discovery technology platforms
  • Enabling technologies, such as biomarkers and imaging
  • Digital platforms, such as wearables
  • Discovery projects
  • Pre-clinical projects
  • Early and mid-stage development projects
  • Regional and global commercialised products

 

Successful partnerships, from early-stage science to commercialisation, have been one of the main drivers in establishing Lundbeck’s current position in brain science. We actively seek access to external innovation, particularly where we see best-in-class opportunities to develop transformative medicines, and where we can leverage our own global drug development and commercial expertise to bring new medicines to patients.

 

Our partnerships are equally valued, whether small or large, which allows us to fine-tune each partnership according to specific needs and circumstances. Across our therapeutic, technological and research areas, we seek: 

Strategic partnerships

 

  • In-licensing
  • Out-licensing
  • Open innovation
  • Academic collaborations
  • Acquisitions
  • Equity investments

Current Partnerships & Alliance Management

The treatments we have launched over the last 10 years demonstrate Lundbeck’s ability and commitment to establishing exceptional partnerships. Once we’ve entered into a partnership, our Strategic Alliance Management Team takes the lead on laying the foundation for a well-functioning relationship. Some of our longstanding valued partnerships include:

Local and Global Deals

Neurological and psychiatric diseases are global issues. Therefore, we seek to leverage our innovative culture, expertise and reputation to build on our global presence by bringing innovative therapies to each and every market. 

 

To explore partnering opportunities, please

More from Lundbeck

Scientific Partnerships

Our heritage and success have provided us with a strong global network.

Sustainability

Lundbeck remains committed to sustainability.

Our Commitment

We strive for Progress in Mind - our multifaceted approach to patients.

UK-NOTPR-0524 | April 2022